Innovus Pharma Beyond Human Platform, Reaching Between 20-30 Million People On A Monthly Basis, Propels High Margin Sales -- SECFilings.com
REDONDO BEACH, CA--(Marketwired - September 19, 2016) - SECFilings.com, a leading financial news and information portal offering free real time public company filing alerts, announces an article discussing the unique, efficient and high-margin Beyond Human sales and marketing platform. The platform has become the cornerstone for Innovus Pharmaceuticals' (OTCQB: INNV) ongoing success and revenue growth.
Innovus acquired Beyond Human LLC in February for $630,000 in cash and the deal is already paying big dividends. During the second quarter, the company reported a 455% increase in revenue to a record $1 million with $256,000 in operating cash flow. Management stated that the company is on track to reach $5 million in revenue for the full year of 2016 -- and that doesn't include any revenues from FlutiCare™ or other high-profile upcoming product launches.
Innovus Pharmaceuticals gained more than just a handful of successful products with the acquisition of Beyond Human -- they gained access to a print media network reaching between 20-30 million people on a monthly basis in the U.S. Innovus also gained a very large number of online email subscribers, pushing the company's total number of subscribers to about 1.5 million people.
The company's marketing team develops editorial content that is pushed through the platform's distribution channels to drive inbound sales calls. A 75-person call center takes care of inbound sales and upsells customers on additional products. For example, a person that calls to purchase the Beyond Human Testosterone Booster might also order Vesele®, since it's a complementary product for that particular demographic.
Vesele® is a great example of why the marketing platform has become so important to Innovus Pharma. After acquiring the product from Trophikos for $40,000 in 2014, the company re-launched the product on the Beyond Human platform and has already generated the bulk of the $1M reported in Q2 2016 along with the testosterone booster product. These revenues also contributed to higher profit margins of 68% in 2016 compared to 58% in 2015 since there are fewer overhead costs and third parties involved in the sales process. The company announced the launch of a third product, RecalMax™, on the same platform a few weeks ago and per the company's presentation at the Rodman & Renshaw Conference in New York on September 12, 2016, the product is selling very well and is on track to being another large product for Innovus.
To read the full article please click here: http://analysis.secfilings.com/articles/66-innovus-innv-beyond-human-platform-reaching-between-20-30-million-people-on-a-monthly-basis-propels-high-margin-sales
About SECFilings.com
Founded in 2004, SECFilings.com provides free real time filing alerts to over 600,000 registered members and offers services to help public companies grow their audience of interested investors.
Disclaimer:
Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC, which owns SECFilings.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Emerging Growth LLC may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit: http://secfilings.com/Disclaimer.aspx.